File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells

TitleMicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells
Authors
KeywordsTemozolomide
MicroRNA
Glioblastoma
Epigenetics
Chemoresistance
Issue Date2012
PublisherInternational Institute of Anticancer Research. The Journal's web site is located at http://ar.iiarjournals.org/
Citation
Anticancer Research, 2012, v. 32 n. 7, p. 2835-2841 How to Cite?
AbstractBACKGROUND: Glioblastoma multiforme (GBM) is a form of highly malignant brain tumour. Temozolomide (TMZ) is the standard agent for GBM, but TMZ-resistance is common and accounts for many treatment failures. MicroRNA-21 (miR-21) is a non-coding RNA that plays critical roles in many biological processes in cancer, including chemoresistance. We investigated miR-21 expression and the effect of miR-21 inhibition in GBM with acquired TMZ resistance. MATERIALS AND METHODS: Human GBM cell line D54MG was treated with TMZ chronically to develop a chemoresistant subclone. MiR-21 inhibition was achieved by transfection with anti-mir-21 oligonucleotide. RESULTS: Chronic TMZ exposure resulted in acquired TMZ-resistance and elevated miR-21 expression. Concomitant treatment with miR-21 inhibitor and TMZ resulted in a significantly higher apoptotic rate than TMZ treatment alone. CONCLUSION: MiR-21 may have a potential for use as a biomarker of acquired TMZ resistance. MiR-21 inhibition can be further explored as a potential chemotherapy adjunct in the treatment of TMZ-resistant GBM.
Persistent Identifierhttp://hdl.handle.net/10722/159947
ISSN
2015 Impact Factor: 1.895
2015 SCImago Journal Rankings: 0.815
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, STSen_HK
dc.contributor.authorZhang, Xen_HK
dc.contributor.authorZhuang, JTFen_HK
dc.contributor.authorChan, HLen_HK
dc.contributor.authorLi, CHen_HK
dc.contributor.authorLeung, GKKen_HK
dc.date.accessioned2012-08-16T05:59:42Z-
dc.date.available2012-08-16T05:59:42Z-
dc.date.issued2012en_HK
dc.identifier.citationAnticancer Research, 2012, v. 32 n. 7, p. 2835-2841en_HK
dc.identifier.issn0250-7005en_HK
dc.identifier.urihttp://hdl.handle.net/10722/159947-
dc.description.abstractBACKGROUND: Glioblastoma multiforme (GBM) is a form of highly malignant brain tumour. Temozolomide (TMZ) is the standard agent for GBM, but TMZ-resistance is common and accounts for many treatment failures. MicroRNA-21 (miR-21) is a non-coding RNA that plays critical roles in many biological processes in cancer, including chemoresistance. We investigated miR-21 expression and the effect of miR-21 inhibition in GBM with acquired TMZ resistance. MATERIALS AND METHODS: Human GBM cell line D54MG was treated with TMZ chronically to develop a chemoresistant subclone. MiR-21 inhibition was achieved by transfection with anti-mir-21 oligonucleotide. RESULTS: Chronic TMZ exposure resulted in acquired TMZ-resistance and elevated miR-21 expression. Concomitant treatment with miR-21 inhibitor and TMZ resulted in a significantly higher apoptotic rate than TMZ treatment alone. CONCLUSION: MiR-21 may have a potential for use as a biomarker of acquired TMZ resistance. MiR-21 inhibition can be further explored as a potential chemotherapy adjunct in the treatment of TMZ-resistant GBM.en_HK
dc.languageengen_US
dc.publisherInternational Institute of Anticancer Research. The Journal's web site is located at http://ar.iiarjournals.org/en_HK
dc.relation.ispartofAnticancer Researchen_HK
dc.subjectTemozolomideen_HK
dc.subjectMicroRNAen_HK
dc.subjectGlioblastomaen_HK
dc.subjectEpigeneticsen_HK
dc.subjectChemoresistanceen_HK
dc.subject.meshAntineoplastic Agents, Alkylating - pharmacology-
dc.subject.meshBrain Neoplasms - drug therapy - genetics - therapy-
dc.subject.meshDacarbazine - analogs and derivatives - pharmacology-
dc.subject.meshMicroRNAs - antagonists and inhibitors - biosynthesis - genetics-
dc.subject.meshOligonucleotides, Antisense - administration and dosage - genetics-
dc.subject.meshGlioblastoma - drug therapy - genetics - therapy-
dc.subject.meshCell line, Tumor-
dc.subject.meshCombined modality therapy-
dc.subject.meshGenetic therapy-
dc.subject.meshTransfection-
dc.subject.meshTumor markers, Biological - genetics-
dc.titleMicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cellsen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, STS: wongtsa@hkucc.hku.hken_HK
dc.identifier.emailLeung, GKK: gilberto@hku.hk-
dc.identifier.authorityWong, STS=rp00478en_HK
dc.identifier.authorityLeung, GKK=rp00522-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid22753745-
dc.identifier.scopuseid_2-s2.0-84865681797en_HK
dc.identifier.hkuros204721en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84865681797&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume32en_HK
dc.identifier.issue7en_HK
dc.identifier.spage2835en_HK
dc.identifier.epage2841en_HK
dc.identifier.isiWOS:000306254300051-
dc.publisher.placeGreeceen_HK
dc.identifier.scopusauthoridLeung, GKK=35965118200en_HK
dc.identifier.scopusauthoridLi, CH=55350085900en_HK
dc.identifier.scopusauthoridChan, HL=55350191800en_HK
dc.identifier.scopusauthoridZhuang, JTF=55349967100en_HK
dc.identifier.scopusauthoridZhang, XQ=52264807800en_HK
dc.identifier.scopusauthoridWong, STS=55308773700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats